• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:02:51 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email
    podd-20250508
    0001145197FALSE00011451972025-05-082025-05-08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF
    THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): May 8, 2025
     
    INSULET CORPORATION
    (Exact Name of Registrant as Specified in Charter)

    Delaware001-3346204-3523891
    (State or Other Jurisdiction
    of Incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    100 Nagog Park
    ActonMassachusetts01720
    (Address of Principal Executive Offices, including Zip Code)
    Registrant’s telephone number, including area code:
    (978)600-7000
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act☐




    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 Par Value Per Share
    PODDThe NASDAQ Stock Market, LLC



    Item 2.02.Results of Operations and Financial Condition.
    On May 8, 2025, Insulet Corporation (the “Company”) announced its financial results for the first quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
    The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01.Financial Statements and Exhibits.
    (d)Exhibits.

    Exhibit
    No.
    Description
    99.1
    Press Release dated May 8, 2025




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
      INSULET CORPORATION
    May 8, 2025  By: /s/ Ana M. Chadwick
    Ana M. Chadwick
    Chief Financial Officer, Executive Vice President

    Get the next $PODD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    12/21/2023$180.00 → $238.00Neutral → Outperform
    Robert W. Baird
    12/4/2023$185.00 → $234.00Equal-Weight → Overweight
    Morgan Stanley
    10/2/2023$260.00 → $240.00Hold → Buy
    Jefferies
    More analyst ratings

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

      New Diabetes Canada Guidelines1 recommend people with type 1 diabetes use an Automated Insulin Delivery System (AID) System for diabetes managementApproximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year2The Omnipod 5 System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in hypoglycemia3OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5 is now

      4/7/25 7:07:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria covered exercise/tax liability with 1,765 shares, decreasing direct ownership by 11% to 14,263 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      5/5/25 4:53:31 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • New insider Mcevoy Ashley claimed ownership of 4 shares (SEC Form 3)

      3 - INSULET CORP (0001145197) (Issuer)

      5/2/25 4:19:13 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Former President and CEO Hollingshead James covered exercise/tax liability with 3,587 shares, decreasing direct ownership by 6% to 61,247 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      4/30/25 4:25:11 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      11/12/24 12:53:28 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      10/7/24 11:37:08 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      2/13/24 5:06:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $PODD
    SEC Filings

    See more
    • Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INSULET CORP (0001145197) (Filer)

      5/8/25 4:02:51 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Insulet Corporation

      DEF 14A - INSULET CORP (0001145197) (Filer)

      4/29/25 4:05:45 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Corporation filed SEC Form 8-K: Leadership Update

      8-K - INSULET CORP (0001145197) (Filer)

      4/28/25 4:13:09 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Insulet downgraded by Wolfe Research

      Wolfe Research downgraded Insulet from Outperform to Peer Perform

      4/29/25 8:07:24 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Insulet with a new price target

      RBC Capital Mkts initiated coverage of Insulet with a rating of Outperform and set a new price target of $340.00

      3/6/25 7:30:36 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Bernstein initiated coverage on Insulet with a new price target

      Bernstein initiated coverage of Insulet with a rating of Outperform and set a new price target of $300.00

      11/6/24 6:20:05 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Financials

    Live finance-specific insights

    See more
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210

      4/3/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

      Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an

      2/20/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care